Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix (NASDAQ: NAOV) has successfully completed the pilot phase of a Randomized Control Trial study for UroShield® at the University of Michigan. The study, primarily conducted with nursing home residents, focused on evaluating UroShield's impact on reducing urinary tract infections, catheter blockages, and pain associated with long-term urinary catheter use.

The completed pilot phase served as a validation step before advancing to the full study, which is expected to commence in 2025. The research team has achieved their initial goals, including refining recruitment strategies and developing data collection tools. This research complements previous studies and product launches in the UK, Australia, and New Zealand, as well as the recent introduction to the European market. The company is simultaneously preparing for a U.S. launch, pending FDA 510K clearance.

NanoVibronix (NASDAQ: NAOV) has renewed its exclusive distribution agreement with Ultra Pain Products (UPPI) for PainShield distribution for another five years. The agreement includes a minimum purchase commitment of $12 million. The renewal follows UPPI's significant growth over the past four years and its evolution in the non-opioid pain management and injury recovery industry.

The collaboration aims to strengthen both companies' market presence, with UPPI continuing to distribute NanoVibronix's proprietary PainShield as part of its expanding portfolio of technologies. The partnership focuses on providing innovative non-opioid treatment options while prioritizing safety, efficacy, and accessibility in the U.S. market.

NanoVibronix, a medical device company, provided a business update highlighting recent developments. CEO Brian Murphy emphasized progress in expanding distribution, raising commercial awareness, and pursuing reimbursements. The company's products, including UroShield®, PainShield®, and WoundShield®, continue to show high patient satisfaction.

The company signed a letter of intent with Kriel Technology Group to explore UroShield distribution in South Africa, with a market evaluation planned for early next year. Independent research presented at major medical conferences demonstrated UroShield's effectiveness in reducing catheter-associated urinary tract infections (CAUTIs).

Reimbursement efforts include a successful application for UroShield actuators on NHS Prescription Services' Drug Tariff and ongoing submissions for full reimbursement in the UK and Germany. The company remains optimistic about expanding its market presence and increasing product awareness globally.

NanoVibronix (NASDAQ: NAOV) has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH, a German pharmaceutical company specializing in urology products. The agreement aims to distribute UroShield throughout Europe. UroShield is an ultrasound-based device designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, potentially reducing catheter-associated urinary tract infections (CAUTI) and associated pain.

Brian Murphy, CEO of NanoVibronix, expressed enthusiasm about partnering with APOGEPHA, citing their leadership in urology and large sales and marketing team as key factors for accelerating UroShield sales in Germany. Dr. Dirk Pamperin, Chairman of APOGEPHA's Management Board, stated their commitment to offering high-quality urological products and their confidence in UroShield's ability to support patients with long-term catheters.

NanoVibronix, Inc. (NASDAQ: NAOV) has signed a letter of intent with Medici Medical , a leading distributor of medical products in Israel, to explore distribution opportunities for its UroShield device in the Israeli healthcare market. This potential partnership aligns with NanoVibronix's strategy to expand distribution and accelerate market adoption of UroShield through established channels.

Brian Murphy, CEO of NanoVibronix, emphasized the importance of partnering with leading distributors to drive market adoption. Medici's CEO, Nufar Cohen, expressed interest in UroShield's reported benefits and plans to evaluate it further through market research. Medici specializes in importing, marketing, and distributing disposable medical devices and has established partnerships with international pharmaceutical companies.

NanoVibronix (NASDAQ: NAOV) reported significant growth in Q2 2024, with revenue reaching $817,000, over 2.5 times higher than Q2 2023. The company reduced its loss from operations by more than 30% to approximately ($674,000). Key highlights include:

1. Increased revenues from Veterans' Health System and Workers' Compensation markets
2. Strong balance sheet with $2.2 million cash and $2.4 million inventory
3. Progress in domestic sales channels, including VA facilities and DME distributors
4. International expansion in Australia, New Zealand, and the UK
5. Ongoing product development and research initiatives

The company remains focused on expanding distribution channels, nurturing relationships with accounts, and engaging consumers to drive profitable growth.

NanoVibronix (Nasdaq: NAOV) announced the start of the pilot phase for the UroShield clinical trial at the University of Michigan. This phase is the initial part of a broader study, following a Research Agreement signed on November 28, 2023. The trial aims to evaluate UroShield's efficacy in reducing urinary tract infections, catheter blockage, and pain, thereby enhancing patient quality of life. The pilot phase involves up to 30 patients, while the full study will involve approximately 300 patients, primarily from nursing homes. The goal is to gather data that will support an application for permanent FDA clearance or approval.

NanoVibronix (NASDAQ: NAOV) issued an update on its business developments and financial performance for Q1 2024. The company reported record first-quarter revenues of $921,000, but also a loss from operations of $568,000. Cash reserves stand at $2.7 million with $2.6 million in inventory. Domestic sales, particularly within the Veterans Affairs (VA) and worker’s compensation markets, are seeing growth, aided by a new General Services Administration (GSA) grant effective May 1, 2024. Internationally, the company has made strides in the UK, Australia, and New Zealand. A significant research study on UroShield by the University of Michigan is underway, potentially bolstering FDA approval efforts. The company is also focused on improving existing products and exploring new opportunities. Key goals include expanding distribution channels and achieving broader market coverage.

NanoVibronix (NASDAQ: NAOV) announced a distribution agreement with CB Medical, a VA-certified and Service-Disabled Veteran-Owned Small Business, for the sale and distribution of UroShield. UroShield, an ultrasound-based device, helps prevent bacterial colonization on urinary catheters, reduces catheter-associated urinary tract infections (CAUTI), and alleviates pain and discomfort. The multi-year agreement allows CB Medical to sell UroShield throughout the VA system in the U.S. Brian Murphy, CEO of NanoVibronix, highlighted the opportunity to expand UroShield's distribution and benefit veterans. Shawn Pinkston, CEO of CB Medical, emphasized the importance of offering effective solutions to veterans, especially those with spinal injuries who use indwelling catheters and are at high risk of infection.